Novo Nordisk is a global leader in diabetes care. Novo has today expanded its portfolio menu with rare treatments for obesity and other chronic conditions. Novo Nordisk is committed to pioneering scientific breakthroughs expanding access to their medicines and strengthening its position in the pharmaceutical industry.
Novo Nordisk Net Worth
Founded in the year 1923, Novo Nordisk’s Net Worth stands at $628.74 billion. This makes it one of the world’s most valuable and noteworthy pharmaceutical companies. In its financial year’s performance, acquisitions and business the company has seen a noteworthy net worth growth over the years. Here’s a complete understanding of Novo Nordisk’s net worth growth trajectory from 2019 to 2023.
Novo Nordisk’s Net Worth Between 2019 to 2020
Between the years 2019 to 2020, the company’s net worth was $139.12 billion and $163.07 billion. From the year 2019 to 2020 the company saw a significant growth of 17.22% which was due to the growth in the sales of its diabetes and obesity segments, even during the pandemic the company managed to maintain its performance in the market.
Novo Nordisk’s Net Worth Between 2020 to 2021
Between this period the company saw a net worth growth of 56.42% with $163.07 billion in 2020 and $255.07 billion in 2021. The growth during this period was attributed to the successful launch of its new diabetes treatment and global demand for insulin and GLP-1 products.
Novo Nordisk’s Net Worth Between 2021 to 2022
After the company expanded its portfolio and ventured into new therapeutic areas like obesity and rare blood disorders, the company saw a 19.38% rise in its net worth. It increased from $255.07 billion to $304.50 billion in 2022.
Novo Nordisk’s Net Worth Between 2022 to 2023
There was an impressive jump of 51.46% in between these years when the company saw an increase in net worth from $304.50 billion to $461.21 billion. Its contribution during this time was its impressive performance in diabetes and obesity treatment and medications.
Novo Nordisk’s Profit and Loss
Novo Nordisk’s core business comes from its manufacturing and marketing of pharmaceutical products in diabetes and obesity care. In Q1 2024, the company reported net sales of $9,50,68,96,400 which marked a 22% increase from the last year. Its profit and loss journey is dependent on its assets and liabilities which are attributed to $631.30 billion and $12.94 billion respectively.
Novo Nordisk’s Assets & Liabilities
Novo Nordisk’s total assets amount to $631.30 billion which includes some investments it made in the research and developments of diabetes and obesity care products. The company’s liabilities amount to $12.94 billion which includes both short-term and long-term investments for the company’s growth and operational expenses.
| Years | Total Assets | Current Assets | Total non-current assets | Total Liabilities |
|---|---|---|---|---|
| 2023 | $314 million | $140 million | $174.84 million | $207.93 million |
| 2022 | $241 million | $108 million | $133.06 million | $157.77 million |
| 2021 | $195 million | $86 million | $108.91 million | $123.76 million |
| 2020 | $144.92 million | $65.81 million | $79.11 million | $81.60 million |
Novo Nordisk’s Stock Market Year On Year
Novo’s stock has seen an impressive performance over the years. The average stock price for Novo Nordisk in 2024 amounted to $142.74 reflecting a year on year of growth of 70.40%.
| Year | Average Stock Price | Year Over Year % |
Current Business
|
|---|---|---|---|
| 2024 | $142.74 | 70.40% | Novo Nordisk |
Year Over Year Growth Numbers:
2021: $256.69 billion (55.86%)
2022: $306.08 billion (19.24%)
2023: $471.73 billion (54.12%)
2024: $628.74 billion (34.26%)
Novo Nordisk’s New Acquisition & Its Business
The company announced the acquisition of three fill-finish sites from Novo Holdings to expand its production capabilities. It is anticipated to be finished by the end of 2024.
| Sr No | Company Name | Bought At | Current Business |
|---|---|---|---|
| 1 | Fill-finish sites (Novo Holdings A/S) | Undisclosed | Enhancing production capabilities in diabetes and obesity care |
No schema found.
